



**Charles SWANTON**

2024 Louis-Jeantet-Collen Prize for Translational Medicine

Charles SWANTON, of British nationality, is awarded the 2024 Jeantet-Collen Prize for Translational Medicine for his groundbreaking discoveries in cancer genetics and evolution, leading to insights into how tumours evolve, spread, and develop resistance to drugs.

Charles Swanton completed his MD-PhD in 1999 at the Imperial Cancer Research Fund Laboratories and his Cancer Research UK (CRUK) clinician scientist/medical oncology training in 2008. Since 2013 he has been Principal Group Leader at the Francis Crick Institute in London and has recently taken on the role of Deputy Clinical Director. He was appointed Chair in Personalised Medicine at University College London Cancer Institute and Consultant Thoracic Medical Oncologist at University College London Hospitals in 2011. He is the Chief Investigator of the CRUK TRACERx lung cancer evolution study and co-directs the CRUK Lung Cancer Centre of Excellence, and in 2017 – he was appointed CRUK’s Chief Clinician.

Charles Swanton was elected as a member of the European Molecular Biology Organization (EMBO) in 2017 and was made a Fellow of the Royal Society in 2018. Throughout his career, he has been honoured with awards and recognitions, including the Memorial Sloan Kettering Paul Marks Prize (2021), the Massachusetts General Hospital Kraft Prize for cancer research (2018) and the San Salvatore Prize for cancer research (2017). He was appointed Napier Professor in Cancer by the Royal Society in 2016.

